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SUMMARY
The robust survival of stereotaxic adrenal
medullary autografts in monkey brain paren-
chyma depends heavily on technique/11/. One
aspect of technique critical for clinical applica-
tions ofCNS grafting is the problem ofspreading
treatment effects throughout large regions in a
primate brain. Stereotaxic placement of a large
number ofgrafts, which would address this prob-
lem, would require that later grafts retain the
capacity for viability over a long period of time
during the surgery, while earlier grafts are being
made. In the present experiments involving 12
longtailed macaques (Macaca fascicularis), some
grafts remained in medium 2.5 h before being
transplanted, without apparent loss ofviability.
A clinically sufficient distribution of graft tis-
suewould also require a large number ofseparate
grafts to be derived from one adrenal medulla.
Onemethod for subdividing the gland might be to
cut it into numerous very small pieces, but vari-
ous dicing techniques described in this report
have yielded little viable graft tissue. On the
other hand, the number of ribbon grafts of the
original dimensions available from a single gland
is rather small; adrenal ribbons of the original
dimensions were therefore further dissected.
Half-length and half-width ribbons were success-
ful, but less so than full-size ribbons in terms of
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proportionate viability. An assay of behavioral
effectiveness, applied to all subjects described
here, is presented in a separate contribution/9/.
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INTRODUCTION
Transplantation as a treatment for Parkinson’s
disease and its animal models was conceived as a
means ofproviding catecholamine for denervated
dopamine terminal areas/5, 19, 31/. Few clinical
surgeries, however, have attempted to distribute
transplant tissue throughout the neostriatum/15/;
most have placed diced autologous adrenal med-
ullary tissue in a cavity in the ventricular aspect of
the caudate nucleus/26, 27/. Viability of adrenal
grafts, moreover, has been minimal in human pa-
tients at autopsy/3, 14, 23, 24, 29/, and in early
non-human primate recipients/4, 20, 28/. The
original concept of transplantation as a neuro-
transmitter replacement therapy has not been
tested by these surgeries. Rodent experiments
have often indicated that grafts are more viable at
ventricular or cavitation sites than at in-
traparenchymal sites/17/, and that fetal nigral tis-
sue is more effective than adrenal autograft tissue
/18/; because of the small size of the rodent brain,
these results are consistent with a neurotransmit-
ter replacement interpretation, particularly for
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nigral grafts, which can reinnervate a significant
portion of the striatum/16/. A test of catechola-
mine replacement as a therapy in primates, how-
ever, will require new methods adapted to larger
brains.
We recently developed techniques for making
viable intraparenchymal adrenal grafts in non-
human primate brains/8, 11/. The grafts retained
tyrosine hydroxylase immunoreactivity and glan-
dular morphology for at least eight weeks. Since
these methods differed substantially from those
previously employed in clinical or animal experi-
ments, it may be that viability depends as much on
transplantation technique as on graft site, host
species, or source of tissue. Intraparenchymal
adrenal medullary grafts in monkeys may repre-
sent a feasible method for distributing grafts and
testing the catecholamine replacement concept in
a large-brained animal.
The present experiments test two aspects of
increasing the number of grafts: (i) increasing the
number of grafts available from an adrenal gland
by dividing larger ribbons into smaller ribbons,
and (ii) leaving a long interval between adrenal
ligation and ribbon transplantation so that multi-
ple grafts can be made in sequence. Histological
evidence indicates that downsizing adrenal rib-
bons by further dissection decreases proportional
viability, but that a prolonged incubation in
vehicle at room temperature may even increase
viability. Histological results of these experi-
ments and those already reported/11/are com-
paredwith results ofearlier transplants employing
a variety of tissue-fragment techniques.
MATERIALS AND METHODS
Subjects
Graft techniques were developed in a series of
24 surgeries on young adult male longtailed ma-
caques (Macaca fascicularis). The first 13 mon-
keys (A1-B4; Table 1) received grafts as small
pieces or slurries. The remaining 11 monkeys
(B5-B15; Table 2) received ribbon grafts by
preliminary (B5-B8)or well-developed (B9-B12)
versions of the ribbon method, or by further ex-
perimental versions involving grafts cut to half-
length and half-width (B!3-B15). Histologica!.
results and grafting methods, whichwere reported
previously for B1-B12/8, 11/, are presented here
forA1-A9 andB13-B15. Behavioral data on all 24
monkeys are presented in a separate report/9/.
Lesion Surgery
Each monkey was anesthetized with
ketamine/halothane and positioned in a Kopf
stereotaxic apparatus with adjustable elevated
eyebars and earbars/10/. Ventriculography was
performed as described previously/10/but with
iohexol (Sterling Winthrop, Rensselaer NY, 180
mgI/ml) as the radio-opaque comrast medium,
injected 19 mm anterior and 2mm left of earbar
zero, at the depth (usually 17-21 mm dorsal) at
which the backflow of cerebrospinal fluid moved
a small air bubble in the line. Polyvinyl tubing
(Bolab, Lake Havasu City AZ, #BB317-V/3) and
a 3-cc syringe were used for injecting iohex01 (0.5
cc over 30 sec) through a 23-ga thinwall cannula
for a frontal X-ray, and again for a lateral view.
Devices for accurately aiming the X-ray and for
later adjusting the eyebars have been described
previously/10/.
The eyebar adjustment to level the intercom-
missural line, and the coordinates of the anterior
commissure after this adjustment, were calculated
from the locations of the commissures in the
lateral X-ray/7/. Stereotaxic coordinates in this
adjusted space for a set of four tracks to deliver
6-hydroxydopamine (8/zg//zl Ringer’s solution,
with 0.1% ascorbic acid) to the substantia nigra
were 4, 6, 8, and 10mm behind the anterior com-
missure and 2mm off midline. The deepest level
for each track (5, 6, 7, and 7.5 mm below the
anterior commissure, respectively) received 3
over 3 min, then the needle was raised in 0.5-mm
increments, and 1.5/zl was injected at each of five
more levels. For monkeys A1-A3, 6-hydroxy-
dopamine injections were made along only the
three anterior tracks. Formonkeys A1-B8, lesions
were created via a surgically implanted cranial
guide-tube platform /6/; transplants were also
made through the platform guide tubes for these
monkeys, except B5 and B7 (Table 2). Lesions
and transplants in monkeys B9-B15 were created
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directly in surgery under anesthesia, without
a platform.
Transplant Surgery: Monkeys A1-A9
Various tissue-fragment transplant methods
were employed in the earliest series (A1-A9,
Table 1). Grafts were placed in two caudate sites
(A1-A4), two caudate and two putamen sites (A5-
A8), or two sites in the lateral ventricle (A9). The
adrenal gland was cut into pieces and medullary
fragments were isolated by piecemeal dissection
(A1-A2), or the medulla was separated in one
piece from the cortex (A3-A9). Small pieces of
medullawere cutwith a scalpel (A1), punched out
with a sharpened needle (A2), minced with a Mc-
Ilwain tissue-chopper (Brinkman Instruments,
Westbury, NY)(A3-A6), or cross-scalpeled (A7-
A9). Beveled needles of various sizes were
loaded, inserted through platform guide tubes/6/,
and emptied either by the insertion of a stylet
(A1-A2) or by hydraulic pressure (A3-A9). For
monkeysA8-A9, micropipette glass with the outer
diameter of a 23-ga stainless steel needle (0.64
mm) was used for injections, to permit visualiza-
tion ofgraft in the needles and to eliminate micro-
scopic metallic flakes observed at many earlier
graft sites.
A cell-suspension method was tested in
monkey A7. Medullary tissue was cross-scal-
peled, gemly stirred at 37C for 45 min in Hanks’
balanced salts without calcium or magnesium
(HBSS) with 0.02% deoxyribonuclease, 0.04%
collagenase, and 0.2% neutral protease, then fil-
tered (60-/zm mesh), centrifuged, and re-sus-
pended/2/. Cell-suspension (20-601) was placed
in each of the four striatal sites, and in one site in
the substantia nigra.
Three monkeys received daily nerve growth
factor (NGF) injections via platform guide tubes
after transplantation. Injections for monkeys A5
and A8 (7S NGF 5 days/wk, 4.17g in 3/l/day)
were placed at two sites, one betweentheputamen
grafts, and the other in the lateral ventricle.
Monkey A9 received ventricular injections only
(2.5S NGF 5 days/wk, 0.0834/g in 3/l/day).
Transplant Surgery: Monkeys B1-B12
Techniques for monkeys B1-B12, including
post-transplant chronic treatmentwithNGF, have
been described elsewhere /8, 11/: briefly, (i)
monkeys B1-B4 received a small amount (3.5/1)
of a slurry prepared from minced adrenal tissue;
(ii) monkeys B5-B8 received ribbon grafts, but
without preservation of the linear form, and (iii)
monkeys B9-B12 received full-length, full width
ribbon grafts (Tables 1-2).
Transplant Surgery: Monkeys B13-B15
In monkeys B13-B15, variations of the estab-
lished method were applied, including finer need-
les, smaller grafts, a greater concentration of
NGF, a largernumber of sites, and a longer period
between ligation and completion (Table 2). For
monkeysB13 andB14, half-ribbons(4-5mm long)
were transplanted to twice as many sites as for
B11-B12. Extra-thinwalled needle stock (21XX:
19-ga inner but only 21-ga outer diameter) was
fitted with a spinal-needle hub filled with acrylic,
and used for half the grafts in each monkey. For
the other half, a smaller such needle (25XX: 22-ga
inner but only 25-ga outer diameter) was similarly
fitted with a hub. The inner stylet for this needle
was 28-ga and the innermost needle was 34-ga.
For this smaller set, the 5-mm half-ribbons were
split lengthwise. NGF concentrations and chronic
treatments were the same for monkey B13 as for
monkeys B9-Bll, and were 10 times that con-
centration for monkey B14 (2.5S NGF, 1 #g in
60.72 #l/day). Monkey B15 received transplants
via the smaller (25XX) needle at thirteen sites
throughout the striatum. A# 11 scalpel blade was
used for splitting the ribbons lengthwise. The
vehicle and chronic ventricular treatment in-
cluded GM1 ganglioside (45.5 pg in 60.72/l/day)
in HBSS.
Immunohistochemistry
Grafts were evaluated on the basis of tyrosine
hydroxylase (TH) immunohistochemistry by
methods previously published/11, 12/.
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TABLE 1. Techniques: Monkeys A1 B4
A1 A2 A3 A4 A5 A6 A7 A8 A9 B1 B2 B3 B4
Preparation Dissect Dissect Cube Cube Cube Cube Suspend Mince Mince Mince Mince Mince Mince
Vehicle Saline Saline Saline Saline Ringers Ringers HBSS Ringers Ringers Ringers Ringers Ringers Ringers
Additives NGF NGF NGF NGF NGF NGF
Sites c2 c2 c2 c2 c2,p2,vl 2,p2 c2,p2,sl c2,p2 v2 c2,p2 c2,p2 c2,p2 c2,p2
Platform tubes 17ga 17ga 17ga 20thin 16ga 16ga 16ga 16ga 16ga 19thin 19thin 19thin 19thin
Injector 19thin 22thin 19thin 23thin 23ga 23ga 23ga 23 glass 23 glass 19 glass 19 glass 19 glass 19 glass
Loading Push Push Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr
Ejecting Stylet Stylet Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr Hydr
Volume/Length na na 10 ul 8 ul 10 ul* 10 ul 5-61 ul* 20 ul 20 ul 3.5 ul 3.5 ul 3.5 ul 3.5 ul
Ugation-End na 20 30 45 90 71 180 44 48 72 80 83 72
Pump cannula Put,Vent* Put,Vent* Vent* Put Put Put Put
Pump vehicle Ringers Ringers Ringers Ringers Ringers Ringers Ringers
Pump additives NGF NGF NGF NGF NGF NGF
Lesion-Graft 39 59 77 23 25 35 7 21 23 35 34 51 51
Graft-Necropsy 29 21 23 15 21 22 26 23 59 16 34 34 49
Age 5.3 4.5 5.2 3 3.7 3.6 3.1 4.6 3.4 2.5 4.5 4.3 4.3
Wt 2.4 2.3 2.7 2.9 2.2 2.6 2.3 2.5 2.2 2.4 2.8 2.6 2.4
Est. cells 973 126 0 0 489 58 0 10 0 62 13 9 0
Positive sites 2/2 1/2 0/2 0/2 2/4 1/4 0/5 1/4 0/2 3/4 0/4 1/4 0/4
TABLE 2. Techniques: Monkeys B5- B15
B5 B6 B7 B8 B9 B10 Bll B12 B13 B14 B15
Preparation Razors Razors Razors Razors Razors Razors Razors Razors Razors Razors Razors
Vehicle Ringers Ringers HBSS HBSS HB/Gara HB/Gara HB/Gara HB/Gara HB/Gara HEYGara HB/Gara
Additives NGF NGF,Lam NGF NGF NGF NGF NGF NGF Gang
Sites c2,p2 c2,p2 c2,p2 c2,p2 c2,p2 c2,p2 c2,p2,sl c2,p2,sl c5,p5,s2 c5,p5,s2 c6,p7
Platform tubes 16ga 16ga*
Outer Injector 19ga lgga 19ga 19ga 19ga 19ga 19ga 19ga 21XX* 21XX* 25XX
Inner Injector 22ga 22ga 22ga 22ga 22/28ga 22/28ga 22/28ga 22/28ga 22/28ga 22/28ga 28/34ga
Loading Push Push Push Push Pull Pull Pull Pull Pull Pull Pull
Ejecting Stylet Styler Stylet Stylet Reveal Reveal Reveal Reveal Reveal Reveal Reveal
Volume na na 5.0mm 7.7mm 9.8mm 8.1mm 8.2mm 11.1mm 5.0mm 4.5mm 3.gmm
Ugate-End 57 47 50 37 64 53 65 70 144 164 157
Pump cannula Vent Vent Vent Vent Vent Vent Vent Vent
Pump vehicle HBSS HB/Gara HB/Gara HEYGara HBSS HB/Gara HB/Gara HB/Gara
Pump additives NGF NGF NGF NGF NGF NGF Gang
Lesion-Graft 27 15 51 52 38 45 15 14 72 77 27
Graft-Necropsy 35 28 28 28 27 28 56 52 57 56 33
Age 4.9 2 3.8 3.5 4.7 4.5 na na 3.2 3.8 na
Wt 2.7 2.5 2.3 2.3 2.8 3.5 2.2 2.1 2 2.3 2.2
Est. cells 1740 399 5047 1910 3035 25865 15281 49008 2564 5760 6977
Positive sites 3/4 414 414 3/4 414 414 5/5 5/5 9110 10/10 9113
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TABLES I and 2
Preparation. Dissect: pieces cut away with scalpel (monkey A1) or punched out with tubing (monkey A2). Cube: tissue chopper
(200/zm for 19 thin injector, 100/zm for 23 thin injector). Suspend: cross-scalpeling and enzyme incubation. Mince: cross
scalpeling, with scalpels (monkeys A8-Ag) or carbide blades (B1-B4). Razors: razor-blade assemblage. A1-A9: prepared in glass
petri dish. B1-B15: prepared on roughened Teflon plate. B5-B15: ribbons stenciled on wax sheet.
Vehicle, Additives. HBSS: Hanks’ balanced salts without calcium or magnesium. HB/Gara: HBSS with antibiotic Garamycin (0.2
mg/ml). NGF: Nerve growth factor (see text for concentrations). Lam: Laminin (20/zg/ml. Gang: GMI gangloside (0.75 pg//zl).
Sites. c2: two sites in head of caudate, p2: two sites in putamen, vl: one site in ventricle, sl: one site in and above substantia
nigra.
Platform tubes. Gauge ofguide-tube implanted in platform. ^: 19-ga tubing was lowered acutely through 16-ga to top of striatum
to guide injector to site. *: guide-tubes stopped at top of skull; skull drilled just before transplant.
Injector. Gauge of injector containing graft. *half the sites were grafted with 25XX Outer, 28/34-ga Inner Injector.
Loading, Ejecting Push: primarily using Dumont forceps to push tissue in at the tip. Hydr: simple suction to draw slurry into
injector or eject into brain. Pull: 22/28-ga or 28/34-ga used to pull ribbon into injector in standard method. Stylet: pushed with
stylet to eject into brain. Reveal: pulled up outer needle first, exposing graft to brain in linear conformation.
Volume. *: AS: 10/1 in each striatal site, 18 pl in ventricle; A7: 61, 42, 34, 23, and 5/zl in four striatal sites and one nigral site
respectively, ha: not available.
Ligation-end. Time from ligation of adrenal vessel to end of final transplantation (min).
Pump Cannula. Put: needle implanted near putamen graft sites. Vent: needle implanted in lateral ventricle on treated side. *:
no pump, sites injected on weekdays. ^
^: Model 2002 (2-wk pump) implanted in platform. ^: Model 2002 (2-wk pump)
implanted subcutaneously on back. All others: Model 2MLA (4-wk) implanted subcutaneously on back.
Lesion-Graft, Graft-Necropsy. Time from lesion to graft and from graft to necropsy (days).
Age. Age in years at necropsy.
Wt. Weight in kilograms at necropsy.
Est. Cells. Direct cell-counts for gratis with few survivors; estimates for large graft.
Positive sites. Number of sites with immunoreactive tissue/total number of target sites.
Measurement
Because it was assumed that transplants
needed to be set in place as quickly as possible,
photographs or careful measurements ofeach rib-
bon were not taken. The length, width, and thick-
ness of each ribbon graft were roughly estimated
before transplant for monkeys B9-B12, but only
the length for monkeys B13-B15 (Table 3). Cell-
counts for surviving graft tissue in histological sec-
tions were also problematic. As noted for
fluorescence-labeled grafts in rodents/16/, and
confirmed in the present material, densely clus-
tered medullary graft cells are difficult to count
accuratelyand theirlarge numbers in ribbon grafts
made direct cell-counts impractical. Quantitative
assessment was nonetheless necessary for com-
paring the results of graft techniques. For these
reasons, cell numbers were estimated on the basis
ofapproximate cell counts in afew small grafts and
rough areal estimates of all grafts, as follows. For
most monkeys, one 40-/m coronal section was
immunostained every 80 to 160/m. The plane of
section and the linear ribbon grafts were both
perpendicular to the horizontal plane ofthe inter-
commissural line. Often most of the linear extent
of a graft was represented in one or two sections,
although portions appeared in sections as far as
250-300/m anterior or posterior. Skipping dis-
continuities, and focusing on the sections contain-
ing the most positive tissue, I estimated the total
dorsoventral length and the average maximal
width along this length for each graft. Then the
graftwas modeled in concept as a narrow cylinder
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TABLE 3, Graft Dimensions
Monkey Viable Length:Sldatum Viable Cells:Striatum Site Average Tot Viable Tot Viable Percent Original Ribbon
CAU PUT CAU PUT Width Length Cells In STR Length Thickness
B9 2.33 4.60 468 2568 Caudate 0.06 2.20 461 1000/0 12.3 0.8 x 0.8
Caudate 0.03 0.13 7 100% 7.9 0.8 x 0.8
Putamen 0.03 2.10 110 100% 9.5 0.6 x 0.8
Putamen 0.13 2.50 2458 100% 6.7 0.8 x 0.8
BIO 4.89 0.00 8236 0 Caudate 0.16 6.40 9533 39% 7.9 1.0 x 0.6
Caudate 0.08 7.00 2291 0% 7.9 1.0 x 0.4
Caudate 0.18 4.70 8860 51% 8.3 1.0 x 0.6
Putamen 0.13 5.70 5182 0% 8.3 1.0 x 0.4
B11 6.47 1.46 9635 494 Caudate 0.16 3.70 5511 97% 9.1 0.8 x 0.6
Caudate 0.16 3.00 4468 96% 7.5 1.0 x 0.4
Putamen 0.05 1.50 218 40% 8.7 1.0 x 0.8
Putamen 0.09 3.75 1767 23/0 8.7 1.0 x 0.8
Nigra 0.10 5.70 3316 0% 7.1 1.0 x 0.8
B12 7.11 0.42 10634 755 Caudate 0.18 7.70 13720 62/0 11.1 1.0 x 0.8
Caudate O.13 5.20 4727 45% 11.1 1.0 x 0.8
Putamen 0.18 5.30 9444 8/0 11.1 1.0 x 0.8
Putamen 0.13 7.00 6364 00/0 11.1 1.0 x 0.8
Nigra 0.21 5.75 14753 00/0 11.1 1.0 x 0.8
B13 4.35 4.00 186 298 Caudate 0.03 2.00 105 1000/0 5 na
Putamen 0.06 0.65 136 100% 5 na
Caudate* 0.03 2.50 91 86% 5 na
Putamen 0.04 1.75 125 100% 5 na
Caudate* 0.02 0.20 3 100/0 5 na
Putamen 0.00 0.00 0 100/0 5 na
Caudate* 0.07 0.70 200 0% 5 na
Putamen 0,02 1.60 37 100% 5 na
Nigra* 0.05 2.60 378 0/0 5 na
Nigra 0.08 4.00 1489 00/0 5 na
B14 7.12 2.00 2900 216 Caudate 0.04 1.60 149 67% 4.5 na
Caudate* 0.06 3.00 628 100% 4.5 na
Caudate 0.14 1.70 1939 100% 4.5 na
Caudate* 0.02 0.50 7 50% 4.5 na
Caudate. 0.06 1.10 230 100% 4.5 na
Putamen* 0.03 0.80 42 100% 4.5 na
Caudate 0.08 1.10 410 0/0 4.5 na
Putamen* 0.05 1.20 175 100% 4.5 na
Nigra 0.15 1.00 1309 00/0 4.5 na
Nigra* 0.09 1.85 872 00/0 4.5 na
B15 3.21 8.58 1989 4543 Caudate* 0.10 1.50 873 100% 5 na
Putamen* 0.00 0.00 0 100% 3 na
Caudate* 0.07 0.70 200 30% 5 na
Putamen* O.10 1.80 1047 1000/o 4.5 na
Caudate 0.00 0.00 0 100% 4.5 na
Putamen* 0.04 0.80 74 100% 2.5 na
Caudate O.11 1.50 1056 100% 2.5 na
Putamen* 0.09 0.50 236 100% 2.5 na
Caudate* 0.00 0.00 0 100% 4 na
Putamen* 0.10 1.00 582 100% 4 na
Caudate* 0.00 0.00 0 100% 4 na
Putamen* O.10 2.10 1222 75% 4 na
Putamen* 0.10 2.90 1687 1000/0 5 na
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TABLE 3
Viable length. Cumulative DV length of portions of ribbon containing viable tissue (mm).
Viable cells. Estimated number of THoirnmunoreactive cells. (For monkey B9 only one or two sections were available for each
graft and substantial portions may not be documented.)
Site. *: half-width ribbon grafted at this site.
Average width. Mean ML width of viable portions of graft.
Percent in STR. Percentage of graft tissue appearing in the striatum.
Original ribbon. Dimensions before grafting. B13-B15: only length was measured, to shorten surgery time.
ofthe corresponding height and diameter. Count-
able cells in a40-tm circular cross-sectionthrough
the cylinder were estimated at 400 per 0.1 sq mm,
on the basis of approximate cell-counts of small
grafts. As the mean diameter of a cell must be
added to the thickness of the section to compen-
sate for double-counting surface cells /1/, the
cross-section was considered to be 55/m thick.
The number of cells per cross-section, multiplied
by the number of 55-ktm cross-sections in the
cylinder, gave the estimate of the number of cells
in the graft (Tables 1-3).
RESULTS
Monkeys A1-A4
The best graft tissue surviving after 3-4 weeks
was a compact TH-immunoreactive fragment of
medulla in the lateral ventricle ofmonkeyA1 (Fig.
la), but another graft, containing fewer cells, was
found in the caudate parenchyma ofA2 (Fig. lb).
Tracks also contained microscopic black flecks
resembling metallic filings, apparently introduced
by the injectors (Fig. lb). After 3 weeks, no viable
immunoreactive graft tissue could be detected in
monkey A3, and only a few questionable cells in
monkey A4 after 2 weeks; the objects were lightly
stained and had ragged morphology (Fig. 2a).
Monkeys A5-A9
There was a cluster of viable immunoreactive
cells near the NGF injection site in the putamen
of monkey A5 (Fig. 2b); monkey A6 was not
treated with NGF, but a small cluster survived in
the putamen (Fig. 2c). Although these findings
confirmed that parenchymal grafts could survive,
the numbers of cells were very small. Metallic
filingswere again observed in graft sites, evennear
the successful grafts (Fig. 2b). Immnohistochemi-
cal examination revealed no active graft tissue
from the cell-suspension grafts in A7, and only a
few cells, ofpoor morphology, along each track in
monkey A8; the best example was a cluster of cells
in a putamen track near the NGF injections (Fig.
2d). No viable tissue from the ventricular grafts
(monkey A9) could be detected.
Monkeys B1-B12
Results for monkeys B1-B12, summarized in
Tables 1-3, have been described and illustrated
elsewhere/8, 11/. A section through a portion of
a nigral graft, not previously displayed, illustrates
the striking viability of the grafts in B9-B12 (Fig.
3b). Table 3 provides a quantitative comparison
of ribbon-grafted sites in monkeys B9-B15.
Monkeys B13-B15
For these subjects, ribbon grafts were prepared
as described previously /8, 11/, except that all
grafts were cut to approximately 5 mrn length, half
that of earlier ribbon grafts, and some were addi-
tionally bisected to half-width. Most graft sites
contained less viable tissue than expected, even
considering the smaller size ofthe original ribbon.
Of the caudate grafts in B13 (half-width), three of
four contained small clumps of immunoreactive
cells. Three of four putamen grafts (full-width),
contained larger clusters, but fell short of half the
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length of grafts in monkeys B9-B12. One nigral
graft (half-width) had no labeled tissue; the other
(full-width) was a good graft (Fig. 3a), but not on
the scale of earlier full-length, full-width grafts
(Fig. 3b). In monkey B14 the caudate grafts (full-
width) were generally thick but short, ranging over
1-2 mm in length. The putamen grafts (half-
width) were thinner. Both nigral grafts, made 2.5
h after the adrenal was tied off, were viable and 2
mm long (Fig. 4a), among the best grafts in this
monkey. Monkey B15 received 13 grafts, all half-
width. Six of seven grafts in the putamen con-
tained substantial numbers of cells, in clusters
100-200/m wide. Most of these clusters were
short (1-2 mm), but the last two grafts, for which
the time spent in vehicle before grafting was
longest, were 3-4mm (Fig. 4b), close to the length
of the original ribbons. In the caudate, two of six
graftswere similar to those in the putamen, but the
other four contained scattered cells at best, most
of them in the corpus callosum above the caudate
and ventricle; some graft tissue may have been
deposited in the ventricle, leaving little trace.
Fig. 1: Small, dense cluster of TH-immunoreactive cells in the ventral tip of the lateral ventricle in monkey A1 (a), in the
caudate nucleus in monkey A2 (b). Small arrows indicate metallic flecks found at the graft site (b). Magnification
200x, for all figures except Fig. 5a. Scale represents 100/m in 10-/m increments. All figures display the largest
example of a graft site in a given monkey, oriented with the dorsal end up.
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Fig. 2: a. Questionable objects in monkey A4, specifically stained (never observed in non-immune serum control sections),
but lacking typical cellular morphology, b. Best graft in monkey A5, located in the putamen near the NGF injection
site. Small arrow marks a metallic fleck at the site. e and d. Best clusters of cells in monkeys A6 (putamen) and
A8 (putamen).
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Fig. 3: Nigral grafts in monkeys B13 (a) and B12 (b)o
Post-surgical Tissue
Full-width, half-length graft tissue from an ad-
ditional monkey that died a few hours after
transplantation, owing to complications involving
anesthesia, supplements data on graft viability.
Little graft tissue adhered to brain tissue after
frozen-sectioning, but a few of the small strips
were successfully processed and mounted. They
document ribbons of thickness up to 600/,m (Fig.
5a). Most adrenal cells were stained relatively
lightly, but cells along the edges were darker and
very compressed, and cells near the top and bot-
tom were also very darkly stained (Fig. 5b).
DISCUSSION
Several biological and technical aspects of
medullary grafting have been discussed previously
/8, 11./. Other issues are raised by the additional
experiments presented in this report, including
the preparation and size of grafts, incubation prior
to grafting, proper use of injection needles, and
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Fig. 4: Best grafts in monkeys B14 (a, nigra) and B15 (b, putamen), each made more than 2.5 h after adrena.! ligation.
variation of the adrenal medulla among in-
dividuals.
Preparation
Early tissue-fragment methods (Table 1:
monkeys A1-B4) met with minimal, capricious
success by comparison with the ribbon method.
These results were roughly similar to those of
several other published accounts of adrenal graft
histology in monkeys/4, 20, 28/. Ribbon grafts, on
the other hand, consistently yielded large amounts
of viable, immunoreactive tissue (Table 3:
monkeys B9-B 15). Even so, proportional viability
of full-size ribbons was well under 50%; half-
length, half-width ribbons, moreover, yielded
grafts of smaller proportional viability than full-
width ribbons, in the monkeys that received both
sizes (B13-B14). The cut surface therefore ap-
pears to be less viable than the internal portion of
a ribbon; cutting cells at this surface and com-
pressing cells just below may seriously com-
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a
Fig. 5: a, Low-magnification view (85x) of adrenal ribbon a few hours after transplantation. Staining intensity is lower and
morphology less distinct than that of intact adrenal medullary tissue or viable graft tissue 4-8 wks after transplan-
tation, b, High-magnification view (200x) ofthe upper end of the same ribbon, displaying signs of physical disruption
and intensely stained small round objects without nuclei.
promise viability near the cut surface. Other
vulnerable regions may be the dorsal end of the
ribbon, stressed by the suction of the 22/28-ga
needle that grasps it as the ribbon is loaded, and
the cross-cut end of a half-length ribbon; even the
full-width ribbons in monkeys B13 and B14 gave a
smaller proportional yield, presumably because
they were cut to half-length. The acute post-sur-
gical graft (Fig. 5) is consistent with these inter-
pretations; the compressed appearance of cells at
the periphery of the ribbon directly after
transplantationmayhave been due inpart to stres-
ses of cutting and loading. Damage at the
periphery may also compromise the interior of a
ribbon to some extent, since anastomosis with
brain vessels must initially take place at the
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stressed surface. In addition, ribbons of medulla
can be stretched slightly in vitro, and internal por-
tions of the graft may be stretched or broken
during loading.
Physical damage of these kinds may be suffi-
cient to reduce the original ribbon to the nar-
rower, variably discontinuous column of viable
tissue seen in histological sections. Areas in rib-
bon grafts that did survive and were immunoreac-
tive were similar in appearance to intact adrenal
medulla/11/, so that a loss of certain tissue com-
ponents throughout the graft, such as connective
tissue, blood vessels, or a subset of chromaffin
cells, is unlikely to account for the diminution.
Nor could the apparent loss of well over half the
transplanted tissue be attributed to small natural
discontinuities of TH-immunoreactivity owing to
embedded islands of zona reticulata (ZR) tissue,
connective tissue, large vessels, and sinusoids.
Various earlier methods of dicing tissue (A1-
B4) involved more serious problems, which were
evident during the surgery as well as during later
histological evaluation, such as the adherence of
tissue to blades, dehydration of tissue fragments,
inconsistent sizes of adrenal pieces, and inconsis-
tent amounts of vehicle added during dissection.
None of these efforts led to large viable grafts, and
in retrospect, dicing tissue to a small size for
stereotaxic needles probably compromises the
capacity for reperfusion, leaving less integrable
material for viable grafts. Excess cutting, whether
in the preparation of ribbon grafts or tissue-frag-
ment grafts, may diminish viability. Only the rib-
bon method described above led to large-scale
viability. It may be noted that the one prior report
of behavioral effects possibly attributable to
adrenal grafts in monkeys involved large pieces
(lxlx5 mm) of medulla/32/.
Vehicle
The interval between ligation of adrenal ves-
sels and introduction of ribbons to transplant
vehicle is brief (5-10 rain). Once the ribbons are
in vehicle, results clearly indicate that surgical
velocity is not a significant factor. Ribbons that
remained in HBSS with NGF or ganglioside at
room temperature for 2-2.5 hmade stronglyviable
grafts (B13-B15). This has several important im-
plications: the number of grafts to be made is
probably not time-limited; adrenalectomy can be
completed before the monkey is placed in the
stereotaxic device; several hours may be available
for incubation with agents to improve graft func-
tion, and there is tim for detailed measurement
and photography to document each ribbon before
grafting.
NGF was included in the vehicle and incuba-
tion medium for all ribbon-graft surgeries except
one; GM1 ganglioside was substituted in that case
(B15), and the viable grafts in this subject suggest
that NGF incubation is not critical. The salt solu-
tion was HBSS for all successful grafts, but no test
has compared it directly with saline, lactated
Ringer’s, or other media. Chronic ventricular
NGF treatment is not essential for viability, as
judged by results in monkey B12, which received
chronic HBSS alone, and monkey B15, which
received chronic GM1 ganglioside; both animals
had somewhat larger viable grafts than others
receiving comparable ribbons. The concentration
ofNGF chronically infused into the ventricle for
monkey B14 was 10 times that used for B9-Bll
and B13, but did not induce neuronal morphology
in the grafted cells.
Injection needles
Neither a single stainless steel needle (A1-A7)
nor glass tubing (A8-B4) made a satisfactory injec-
tor, nor did any of these experiments yield results
favoring one needle size over another. Early rib-
bon grafts (B5-B8) were mostly loaded by being
pushed in from the tip and injected by being
pushed out with a 22-ga inner needle. Such grafts
were found at the bottom of the track and con-
tained a small proportion of viable tissue, in con-
trast to later ribbon grafts. It is clearly preferable
to load and to eject as described for the ribbon
method/8/. Spinal-needle injector assemblies of
various sizes (19-ga, 21XX, or 25XX; monkeys
B9-B15) yielded substantial survival of medullary
tissue. By comparison with the 19-ga spinal
needle, the21XX needle provided a smaller outer
diameter for the same inner diameter. The thin-
ner injector (25XX) did not appear to increase
viability or to encourage the formation of proces-
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ses by chromaffin cells. The increased amount of
graft trimming and handling involved in loading
the25XX needle probably compromised viability.
This needle also bent more easily, which made
handling more difficult and decreased stereotaxic
accuracy. For all needles, softening the internal
edge of the bevel eased loading. An acid wash
before each surgery, and reuse ofthe same needle
many times, practically eliminated the occurrence
of metallic filings at graft sites for ribbon grafts.
Variation
Biological variation may have a substantial in-
fluence on grafts. For example, the largest grafts
in the present material (B12) were also the largest
pre-transplant ribbons from the largest adrenal
medulla. Variability also affects the ease of
preparation and the degree ofcontamination with
ZR tissue. The adrenal gland varied among the 24
subjects in size, shape, color, ZR and medullary
thickness, strength of adrenal vein musculature,
and tenacity of tissue holding medulla and cortex
together at their interface. For one of the first
subjects, for example, eventhough the edges ofthe
intact gland were not trimmed or the cortex inten-
tionally retracted, as became standard practice for
later monkeys, the piecemeal removal of external
adipose, vascular, and connective tissue from the
intact gland pulled away most of the cortex from
the medullawithout further effort. For other sub-
jects the adherence between these layers was
stronger, and although the orderly dissection
scheme as described/8/has been much more reli-
able than piecemeal dissection, the tissue itself is
nonetheless highly variable among individuals in
this regard.
Corresponding variation was also observed in
a microscopic analysis of a large sample of glands
from rhesus macaques/22/. In that study, there
were variations in the amount ofconnective tissue
and amorphous intercellular material in the ZR,
in the amount of acellular connective tissue form-
ing an incomplete "capsule" between the ZR and
the medulla, and in the numbers of pigmented
cells in bothZR and underlying connective tissue.
These elements were not observed in fetal or very
young monkeys, but otherwise they were unre-
lated to age. Islands of ZR cells are known to be
present in human adrenal medulla/21/, and is-
lands ofTH-immunonegative cells have been ob-
served in monkey adrenal medulla /11/; the
frequency and distribution of these islands, like
those of norepinephrine and epinephrine islands
/13/, are likely to vary among individuals.
Comparison with Other Reports
The ribbon method, like the stereotaxic co-
graft method recently described/25/, has been
relatively reliable in terms of graft viability. Adre-
nal medullary grafts made by the ribbon method
displayed remarkable viability after eight weeks
survival. The viable immunoreactive graft tissue,
however, did not account for the majority of the
volume of the original ribbon. Experiments with
smaller, more sculpted ribbons have indicated
that much of the loss of chromaffin tissue occurs
at the cut surfaces and ends of the ribbons. This
may also be an important observation in the con-
text of clinical medullary grafts that have already
been made, even though very different methods
have been used. Further experimentation with
medullary ribbon grafts in non-human primates
should focus on reducing the stress ofpreparation
at the cut margins of the ribbon.
Owing to biological variability, no two graft
subjects can be strictly comparable. Individual
variation in the raw material of adrenal autografts
has undoubtedly contributed to graft variability in
the present ribbon-graft subjects (B9-B15). The
observation that medullary ribbons can be left in
vehicle for at least 2.5 hours, and possibly much
longer, gives time for detailed photography and
measurement of each graft, so that the influence
of such factors on viability can now be explored.
A principal advantage of stereotaxic grafting is
flexibility in the choice and number of graft sites.
If the reversal of the behavioral effects of nigral
lesions in monkeys requires the replacement of
catecholamines in the striatum, it is important to
determine how many grafts and which locations
are necessary for reversing various effects. A be-
havioral assay, presented in the accompanying
report along with data from all the subjects
described above, initiates this process for ribbon
grafts/9/.
JOURNALOFNEURALTRANSPLANTATION& PLASTICITYVIABLEADRENALMEDULLARYTRANSPLANTS 95
Aside from the subjects described in the pres-
ent report, a total of 34 other non-human primate
subjects have received adrenal grafts/4, 20, 25, 28,
30, 32, 33/. Histological data have been reported
for 30 of these subjects. A variety ofmethods have
been employed, with the sample sizes for any one
method averaging 2.5 animals (range 1 to 4).
Subjects have been intact (5 subjects), lesioned by
IV-N-methylphenyltetrahydropyridine (MPTP)
(2), or unilaterally by intracarotid MPTP (18) or
intracerebral 6-OHDA (5). Grafts have been
made stereotaxically (7), stereotaxically via a sil-
ver carrier (4), stereotaxically after transcallosal
exposure of the caudate (4), or into a cavity in the
caudate nucleus made transcallosally after an
interhemispheric approach (9) or after a trans-
cortical approach (6). A wide range of viable
tissue has resulted from these experiments, from
none (9) or fewer than 100 chromaffin cells/site
(7) to an average of 5500-6000/site (6)/25/; for 8
subjects only qualitative descriptions were given
(a "thin rim" and "small rests" /30/; TH im-
munoreactivity "in cells within the confines of the
graft" and DBH immunoreactivity in "less than
3% of the estimated total, number of grafted
catecholaminergic cells"/32/).
For a variety of reasons, the present report as
well as these previous reports concern case studies
of individual subjects or very small numbers of
subjects for any given set of techniques. These
studies are breaking a trail, not building a highway.
A full-scale critical test of a single given set of
techniques and graft sites would not yet be appro-
priate. From a perspective based on non-human
primate research, the time has not yet arrived for
clinical applications. It is important to examine
closely the techniques, histology, and behavior
reported for each animal in order to use the most
promising techniques for further studies.
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